DECODE GENETICS-*DCGN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DECODE GENETICS-*DCGN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (257)	10/7/2006 11:34:02 AM
From: tommysdad	Read Replies (2) of 313

I think that's biotech thinking, by which I mean not thinking long-term ;o). A ton of information is known about the Bayer drug that is not known about the internal x051. So many, many, many hurdles could trip up x051 -- hurdles that x031 has ALREADY CLEARED. Tablet formulation with x031? Yeah, a problem, but there are plenty of companies out there very capable of helping DeCode fix that. An unanticipated tox finding in a 12-week study on x051 (a study they probably haven't even started yet!)? No fixing that! Let's not ignore the fact that these two drugs hit very different targets, and they really don't know which target is best. Crickey, they don't really know if EITHER target is appropriate for the indication they are pursuing. No, the logical thing to do is carry both forward. As you note, whether or not they have the cash to do so is a question. But, scientifically, it's a no-brainer!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next